ArticleFrontiers in pharmacology2023

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status.

José Manuel Ramos-Rincón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.